FDA approves Fensolvi (leuprolide acetate) for injectable suspension for paediatric patients with central precocious puberty

Tolmar Pharmaceuticals

4 May 2020 - Fensolvi is the only six-month, subcutaneously administered leuprolide acetate approved for the treatment of paediatric patients two years of age and older with central precocious puberty.

Tolmar Pharmaceuticals, Inc. announced today that the U.S. FDA has approved its new drug application for Fensolvi (leuprolide acetate) for injectable suspension for the treatment of paediatric patients two years of age and older with central precocious puberty (CPP). 

CPP is a rare disease defined as the onset of puberty before age eight in girls and before age nine in boys.

Read Tolmar Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US , Paediatrics